Protagonist Therapeutics, Inc.

PTGX Healthcare Biotechnology

Protagonist Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, down 89.4% from fiscal 2024. In the quarter to June 2026, revenue grew 3,749.2%, EPS grew 549.1% and free cash flow grew 839.7%, each against the same quarter a year earlier.

128.75 7.80 −5.71%
Market cap
$8.8B
P/E
106×
Fwd P/E
25.0×
Dividend yield
—
F-score
4/9
Altman Z
61.55
Beneish M
−7.18
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

88.57 0.00 0.00 100.48
P/S ratio
20.25 120.66 92.63 28.66
P/FCF ratio
66.49 99.01 0.00 61.90
P/Operating CF
(2,187.08) (150.17) (140.17) 36.90
P/B ratio
6.56 9.03 10.47 9.60
EV/Sales
17.54 108.55 85.36 25.92
EV/EBITDA
281.36 0.00 0.00 129.65
EV/FCF
57.60 89.07 (53.63) 55.98
Current Ratio
13.05 12.71 17.76 21.71
Net Debt/EBITDA
12.39 11.13 143.14 (4.96)
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
1.13% (2.35%) (1.71%) 1.00%
Free Cash Flow Yield
1.50% 1.01% (1.72%) 1.62%
Free Cash Flow per Share
(0.03) (0.58) (0.76) 3.32
Book value per Share
10.12 9.67 10.07 12.76
Free Cash Flow
(2.02) (37.12) (49.16) 218.88
EV/EBIT
193.08 0.00 0.00 125.29
Other line items

Show all line items

Columns are period end dates